Want to see HK:2393 full AI Analyst Report?
2393 Stock Chart & Stats
HK$0.06
HK$0.00(0.00%)
At close: 4:00 PM EDT
HK$0.06
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.04 - HK$0.14
Previous CloseN/A
Volume70.00K
Average Volume (3M)123.58K
Market Cap
HK$146.77M
Enterprise ValueHK$177.64M
Total Cash (Recent Filing)HK$194.45M
Total Debt (Recent Filing)HK$202.47M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Mar 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.02%
Share Statistics
EPS (TTM)-0.04
Shares Outstanding2,331,590,000
10 Day Avg. Volume148,000
30 Day Avg. Volume123,583
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.56
Price to Sales (P/S)0.14
P/FCF Ratio0.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash GenerationOperating and free cash flow of approximately 311M and 289M in 2025 show strong recent conversion from operations despite reported net losses. If sustained, this internally generated liquidity can support clinic operations and investment without relying as heavily on external funding.
Balance Sheet ImprovementThe move from negative equity to positive equity, alongside lower debt and moderate 2025 leverage, materially reduces balance-sheet strain. Greater financial resilience gives Yestar more capacity to maintain its clinic platform and withstand operating volatility over the next several quarters.
Clinic Network Business ModelA branded clinic network with in-house medical professionals provides a direct platform for delivering elective healthcare services and collecting patient fees. This operating model can support repeat treatments, broader service offerings, and customer relationships within the company’s own facilities.
Bears Say
Revenue ContractionThe sharp latest-period revenue decline indicates weakened demand or clinic volume and reduces confidence in near-term growth. Continued top-line pressure could lower facility utilization, restrict operating leverage, and make it harder for the company to rebuild consistent earnings across its service network.
Unstable ProfitabilityA return to net losses despite positive operating profit shows that earnings conversion remains unreliable. The contrast with the prior period’s unusually high net margin suggests reported profitability is not yet durable, limiting confidence in shareholder returns and internally funded expansion.
Volatile Cash FlowStrong 2025 cash generation is encouraging, but the history of negative operating and free cash flow shows that conversion has not been consistent through the cycle. This volatility may complicate investment planning and reduce certainty that recent liquidity improvement will persist.
Yestar Healthcare Holdings Co Ltd News
2393 FAQ
What was Yestar Healthcare Holdings Co Ltd’s price range in the past 12 months?
Yestar Healthcare Holdings Co Ltd lowest stock price was HK$0.04 and its highest was HK$0.14 in the past 12 months.
What is Yestar Healthcare Holdings Co Ltd’s market cap?
Yestar Healthcare Holdings Co Ltd’s market cap is HK$146.77M.
When is Yestar Healthcare Holdings Co Ltd’s upcoming earnings report date?
Yestar Healthcare Holdings Co Ltd’s upcoming earnings report date is Mar 26, 2027 which is in 145 days.
How were Yestar Healthcare Holdings Co Ltd’s earnings last quarter?
Yestar Healthcare Holdings Co Ltd released its earnings results on Aug 28, 2026. The company reported -HK$0.002 earnings per share for the quarter.
Is Yestar Healthcare Holdings Co Ltd overvalued?
According to Wall Street analysts Yestar Healthcare Holdings Co Ltd’s price is currently Overvalued.
Does Yestar Healthcare Holdings Co Ltd pay dividends?
Yestar Healthcare Holdings Co Ltd pays a Annually dividend of HK$0.055 which represents an annual dividend yield of 2.02%. See more information on Yestar Healthcare Holdings Co Ltd dividends here
What is Yestar Healthcare Holdings Co Ltd’s EPS estimate?
Yestar Healthcare Holdings Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Yestar Healthcare Holdings Co Ltd have?
Yestar Healthcare Holdings Co Ltd has 2,331,590,000 shares outstanding.
What happened to Yestar Healthcare Holdings Co Ltd’s price movement after its last earnings report?
Yestar Healthcare Holdings Co Ltd reported an EPS of -HK$0.002 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Yestar Healthcare Holdings Co Ltd?
Currently, no hedge funds are holding shares in HK:2393
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Yestar Healthcare Holdings Co Ltd
Yestar Healthcare Holdings Company Limited, an investment holding company, manufactures, distributes, and sells medical imaging products in Mainland China. The company operates in two segments, Imaging Printing Products, and Medical Products and Equipment. The Imaging Printing Products segment manufactures and sells color photographic paper and industrial NDT x-ray films and PWB films, as well as trades in imaging equipment. The Medical Products and Equipment segment manufactures and sells medical dry, medical wet, and dental films, as well as sells medical equipment and diagnostic reagents. The company also engages in the management of supply chain and service of freight transportation equipment, as well as development of biotechnology. The company was formerly known as Yestar International Holdings Company Limited and changed its name to Yestar Healthcare Holdings Company Limited in January 2017. Yestar Healthcare Holdings Company Limited was founded in 1971 and is headquartered in Shanghai, the People’s Republic of China.
Technical Analysis
Peijia Medical Ltd.
―
Acotec Scientific Holdings Limited
―
Vincent Medical Holdings Limited
―
Sisram Medical Ltd.
―
Venus Medtech (Hangzhou), Inc. Class H
―